Fujian Wanchen Biotechnology Co. Ltd (300972) — Working Capital to Net Assets Ratio
Fujian Wanchen Biotechnology Co. Ltd (300972) has a Working Capital to Net Assets ratio of 98.4% as of March 2026. Working capital of CN¥3.37 Billion (current assets of CN¥9.50 Billion minus current liabilities of CN¥6.13 Billion) is measured against net assets of CN¥3.42 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how financially flexible is Fujian Wanchen Biotechnology Co. Ltd to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Fujian Wanchen Biotechnology Co. Ltd Working Capital to Net Assets (2019–2025)
This chart shows how Fujian Wanchen Biotechnology Co. Ltd's Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the ratio stands at 98.4%, reflecting working capital of CN¥3.37 Billion against net assets of CN¥3.42 Billion CNY. See Fujian Wanchen Biotechnology Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Fujian Wanchen Biotechnology Co. Ltd (2019–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Fujian Wanchen Biotechnology Co. Ltd from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 300972 stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 102.8% | CN¥2.62 Billion | CN¥2.55 Billion | CN¥8.89 Billion | CN¥6.27 Billion | ▲ +58.8 pp |
| 2024 | 44.0% | CN¥642.52 Million | CN¥1.46 Billion | CN¥5.77 Billion | CN¥5.13 Billion | ▲ +85.8 pp |
| 2023 | -41.8% | CN¥-290.99 Million | CN¥695.81 Million | CN¥2.35 Billion | CN¥2.64 Billion | ▼ -34.0 pp |
| 2022 | -7.9% | CN¥-52.80 Million | CN¥672.36 Million | CN¥278.69 Million | CN¥331.49 Million | ▼ -26.5 pp |
| 2021 | 18.7% | CN¥121.85 Million | CN¥652.71 Million | CN¥302.39 Million | CN¥180.54 Million | ▲ +48.5 pp |
| 2020 | -29.8% | CN¥-119.41 Million | CN¥400.65 Million | CN¥93.13 Million | CN¥212.53 Million | ▲ +8.6 pp |
| 2019 | -38.4% | CN¥-132.55 Million | CN¥344.82 Million | CN¥74.23 Million | CN¥206.78 Million | — |